Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02550873 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02550873 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 117 participants.
The verdict
NCT02550873, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study is a Phase 2, randomized, double-blind, placebo controlled, pilot study designed to evaluate the efficacy and safety of PRM-151 administered through Week 24 to subjects with IPF.
Interventions
- OTHER placebo
- BIOLOGICAL PRM-151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2017-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02550873
The ClinicalTrials.gov registry entry for NCT02550873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02550873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02550873 about?
NCT02550873 is a clinical study titled "A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)". This study is a Phase 2, randomized, double-blind, placebo controlled, pilot study designed to evaluate the efficacy and safety of PRM-151 administered through Week 24 to subjects with IPF.
What is the current status of trial NCT02550873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2015-09-01. Estimated completion is 2017-05-02.
What interventions are being tested in trial NCT02550873?
The interventions under investigation include: placebo (OTHER), PRM-151 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02550873?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.